Article
Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.
The Journal of antimicrobial chemotherapy - 1 Oct 2020
Chen Guan-Jhou, Lee Yu-Lin, Lee Chen-Hsiang, Sun Hsin-Yun, Cheng Chien-Yu, Tsai Hung-Chin, Huang Sung-Hsi, Lee Yi-Chieh, Hsieh Min-Han, Chang Sui-Yuan, Chuang Yu-Chung, Su Li-Shin, Chang Sui-Fang, Tang Hung-Jen, Hung Chien-Ching
Abstract excerpt
OBJECTIVES: Real-world experience regarding the effectiveness of co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (EVG/C/FTC/TAF) as a switch regimen is sparse among people living with HIV (PLWH) harbouring the M184V/I mutation with or without thymidine analogue-associated mutations (TAMs). METHODS: In this retrospective multicentre study, PLWH who were switched to EVG/C/FTC/TAF...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.